latest news releases from the newsroom
North American Galvanizing & Coatings, Inc.
North American Galvanizing & Coatings Announces Filing Preliminary Consent Solicitation
TULSA, Okla., Feb. 24, 2009 (GLOBE NEWSWIRE) -- North American Galvanizing & Coatings, Inc. (Nasdaq:NGA) announced today that it has filed a preliminary consent solicitation with the Securities and Exchange Commission to solicit written consents from its stockholders to approve a proposed amendment to its Restated Certificate of Incorporation, as amended, to increase the authorized shares of common stock from 18,000,000 to 25,000,000. Currently, North American Galvanizing & Coatings, Inc. only has 454,271 authorized shares of common stock available for possible future uses. Possible future uses for the additional shares of common stock include, without limitation: possible future financings, including the sale of common stock, convertible debt or warrants; and possible acquisitions of assets, or interests in, additional geographically strategic hot-dip galvanizing plants or related businesses. North American Galvanizing & Coatings, Inc. has not entered into any binding or non-binding plans, arrangements or understandings regarding the additional shares that would be authorized pursuant to the proposed amendment. North American Galvanizing & Coatings, Inc. hopes to mail definitive materials to its stockholders on March 10, 2009.
Federal Home Loan Bank of Cincinnati
FHLBank Cincinnati Announces 2008 Results
CINCINNATI, Feb. 24, 2009 (GLOBE NEWSWIRE) -- The Federal Home Loan Bank of Cincinnati (FHLBank) today released unaudited financial results for the fourth quarter and year ended December 31, 2008. We believe our financial condition remained strong in 2008 even in the face of the extraordinary events impacting the entire economy, including the credit, banking and mortgage markets. We continued to serve and reinforce our role as an important provider of reliable and attractively priced wholesale funding to members. Highlights include:
Nymox Pharmaceutical Corporation
Nymox Announces New Positive Results At 5 Years After Single Treatment in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia
HASBROUCK HEIGHTS, N.J., Feb. 24, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's two initial 2003 Phase 1-2 studies of NX-1207. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 64 months after treatment.
Levi & Korsinsky, LLP
Levi & Korsinsky, LLP Investigates Breach of Fiduciary Duty by the Board of Hifn, Inc.
NEW YORK, Feb. 24, 2009 (GLOBE NEWSWIRE) -- Levi & Korsinsky ("L&K") is investigating breaches of fiduciary duty and other violations of state law by the board of directors of Hifn, Inc. ("Hifn" or the "Company") (Nasdaq:HIFN) arising out of their attempt to sell the Company to Exar Corporation ("Exar"). Under the terms of the proposal, Hifn's shareholders would be able to elect to receive (i) $1.60 cash and 0.3529 Exar shares for every Hifn share they own, or (ii) $4.00 in cash. The transaction is unfair given that, among other things, the Company's shares traded above $4.00 per share as recently as September 3, 2008 and analysts set a mean price target of $5.50 per share. The proposed acquisition is subject to customary conditions and regulatory approvals.